ST Renfu (600079.SH): HW252001 film obtains the drug clinical trial approval notice.
ST Yinfu (600079.SH) announced that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd., has recently received the Drug Clinical Trial Approval Notification for the HW252001 Tablet issued by the National Medical Products Administration, approving the clinical trial for Idiopathic Pulmonary Fibrosis indication.
ST People's Welfare (600079.SH) announced that its wholly-owned subsidiary, Hubei Bio-pharmaceutical Industry Technology Research Institute Co., Ltd., recently received the Drug Clinical Trial Approval Notice for HW252001 tablets issued by the National Medical Products Administration. The notice approves the clinical trial for the treatment of idiopathic pulmonary fibrosis.
HW252001 tablets are intended for the treatment of idiopathic pulmonary fibrosis and are an oral small molecule new drug. As of now, the project has a cumulative research and development investment of approximately 20 million yuan. Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown etiology, with characteristic histopathological/imaging features, progressive decline in lung function, acute exacerbation, and respiratory failure, with a poor prognosis. The main treatment for IPF is anti-fibrotic drug therapy, used to slow down the decline in lung function and disease progression, with no curative treatment currently available.
Related Articles
CG Services (06098) spent 6.2595 million Hong Kong dollars on December 19 to repurchase 1 million shares.
ZHOU HEI YA (01458) spent HK$78,500 to buy back 45,500 shares on December 19th.
The placement of 98.52 million shares of PACIFIC LEGEND (08547) has been completed.
CG Services (06098) spent 6.2595 million Hong Kong dollars on December 19 to repurchase 1 million shares.
ZHOU HEI YA (01458) spent HK$78,500 to buy back 45,500 shares on December 19th.
The placement of 98.52 million shares of PACIFIC LEGEND (08547) has been completed.
